Observational studyActa oncologica (Stockholm, Sweden)2026
Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study.
Carl Rosander et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.